04.06.2012 - Austrian biotech Nabriva Therapeutics AG has partnered with Forest Laboratories Inc. to develop its antibiotic BC-3781.
Vienna - As part of the deal, Forest will have the exclusive right to acquire Nabriva for the next 12 months. Nabriva will receive US$25m. Forest will also fund and help develop BC-3781 during the period. BC-3781 belongs to a novel class of antibiotics, the pleuromutilins. It is designed to treat severe and drug resistant infections including MRSA, penicillin-resistant Streptococcus pneumonia, Legionella pneumophila, which causes Legionnaires' disease, and Chlamydophila pneumoniae, a major cause of pneumonia.
BC-3781 has potential in both intravenous and oral formulations and the cooperating companies plan to advance it into Phase III testing early next year. Forest said the oral formulation provides an opportunity to treat patients after they leave the hospital and would complement its Teflaro ceftaroline, a cephalosporin antibiotic available only as an intravenous drug.
Nabriva is based in Vienna, and in 2011 it reported positive mid-stage trial results from a Phase IIb study that evaluated BC-3781 as a treatment for acute bacterial and skin structure infections.
25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.
21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.
11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.
04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more